Premium
Metal‐Based Catalytic Drug Development for Next‐Generation Cancer Therapy
Author(s) -
Fan Zhongxian,
Huang Juyang,
Huang Huaiyi,
Banerjee Samya
Publication year - 2021
Publication title -
chemmedchem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.202100297
Subject(s) - nad+ kinase , nicotinamide adenine dinucleotide , chemistry , cancer , combinatorial chemistry , catalysis , drug , cancer therapy , drug development , cancer cell , drug discovery , anticancer drug , pharmacology , biochemistry , cancer research , medicine , enzyme
Considering the high increase in mortality caused by cancer in recent years, cancer drugs with novel mechanisms of anticancer action are urgently needed to overcome the drawbacks of platinum‐based chemotherapeutics. Recently, in the area of metal‐based cancer drug development research, the concept of catalytic cancer drugs has been introduced with organometallic Ru II , Os II , Rh III and Ir III complexes. These complexes are reported as catalysts for many important biological transformations in cancer cells such as nicotinamide adenine dinucleotide (NAD(P)H) oxidation to NAD + , reduction of NAD + to NADH, and reduction of pyruvate to lactate. These unnatural intracellular transformations with catalytic and nontoxic doses of metal complexes are known to severely perturb several important biochemical pathways and could be the antecedent of next‐generation catalytic cancer drug development. In this concept, we delineate the prospects of such recently reported organometallic Ru II , Os II , Rh III and Ir III complexes as future catalytic cancer drugs. This new approach has the potential to deliver new cancer drug candidates.